Aspen's Acquisition of Sigma For APAC Expansion Comes At Time Of Generics Uncertainty In Australia
This article was originally published in PharmAsia News
Executive Summary
TOKYO - South African firm Aspen appears on track to finalize its months-long acquisition attempt of Australia's Sigma Pharmaceuticals, shifting away from its original offer for a full acquisition to a leaner deal in which Aspen will gain Sigma's pharmaceutical division
You may also be interested in...
Merck Sells Dutch API Business To South Africa’s Aspen
Aspen Pharmacare continues a buying spree to boost its presence in Asia and Latin America.
India’s Cipla Partially Exits Desano Of China; Redeploys Funds Into Biosimilars, APIs
The Indian drug maker has embarked on a new China strategy that includes biosimilars.
As User Fee Date Nears, Australia’s QRxPharma Moves To POC For MoxDuo CR Formulation; Secures Actavis As Partner
The company looks to position its dual-opioid combination against Purdue Pharma’s OxyContin.